NA Anthrax Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143111
- Pages: 225
-
Format:
Short Description
North America Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country (U.S., Canada and Mexico) Industry Trends and Forecast to 2029.
Market Definition:
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Market Segmentation:
North America anthrax treatment market is categorized based on type, route of administration and end user.
On the basis of type, North America anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax
On the basis of route of administration, North America anthrax treatment market is segmented into oral, parenteral and others
On the basis of end user, North America anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others
Market Players
The key market players for North America anthrax treatment market are listed below:
Alembic Pharmaceuticals
Integrated Bio Therapeutics Inc.
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi
Elusys Therapeutics
Lupin
Soligenix
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
INDOCO REMEDIES LTD.
Paratek Pharmaceuticals, Inc.
BlueWillow Biologics.
Altimmune
TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE NORTH AMERICA ANTHRAX TREATMENT MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
2.1 MARKETS COVERED 79
2.2 GEOGRAPHICAL SCOPE 80
2.3 YEARS CONSIDERED FOR THE STUDY 81
2.4 CURRENCY AND PRICING 81
2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
2.6 MULTIVARIATE MODELLING 85
2.7 PRODUCT SEGMENT LIFELINE CURVE 85
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.9 DBMR MARKET POSITION GRID 87
2.10 MARKET APPLICATION COVERAGE GRID 88
2.11 VENDOR SHARE ANALYSIS 89
2.12 SECONDARY SOURCES 90
2.13 ASSUMPTIONS 90
3 EXECUTIVE SUMMARY 91
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTERS FIVE FORCES 97
4.3 DEMOGRAPHIC TRENDS- 98
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
4.4.1 INCIDENCE 100
4.4.2 DEVELOPED COUNTRIES- 100
4.4.3 DEVELOPING COUNTRIES- 100
4.5 PATIENT ENROLMENT STRATEGIES- 102
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
4.7 CURRENT STATE OF ANTHRAX VACCINES 108
4.8 NORTH AMERICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
4.9 NORTH AMERICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEARS ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANYS PIPELINE FOR ANTHRAX TREATMENT. 117
6 NORTH AMERICA ANTHRAX TREATMENT MARKET: REGULATIONS 119
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
7.2 RESTRAINTS 127
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
7.2.2 FALSE DATA INTERPRETATION 128
7.3 OPPORTUNITIES 128
7.3.1 RISING PRODUCT LAUNCHES 128
7.3.2 RISING GOVERNMENT INITIATIVES 129
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
7.4 CHALLENGES 130
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
7.4.2 LACK OF SKILLED PROFESSIONALS 130
8 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE 132
8.1 OVERVIEW 133
8.2 CUTANEOUS ANTHRAX 136
8.2.1 ANTIBIOTICS 137
8.2.1.1 BY DRUGS 137
8.2.1.1.1 CIPROFLOXACIN 138
8.2.1.1.2 LEVOFLOXACIN 138
8.2.1.1.3 DOXYCYCLINE 138
8.2.1.1.4 AMPICILLIN 138
8.2.1.1.5 OTHERS 138
8.2.1.2 BY PRODUCT TYPES 138
8.2.1.2.1 GENERICS 138
8.2.1.2.2 BRANDED 138
8.2.1.2.2.1 CIPRO 139
8.2.1.2.2.2 LEVO 139
8.2.1.2.2.3 DOXY 139
8.2.1.2.2.4 AMPICI 139
8.2.1.2.2.5 OTHERS 139
8.2.2 ANTITOXINS 140
8.2.2.1 RAXIBACUMAB 140
8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
8.2.2.4 OTHERS 140
8.2.3 VACCINES 141
8.2.3.1 RAXIBACUMAB 141
8.2.4 SURGERY 141
8.3 PULMONARY ANTHRAX 141
8.3.1 ANTIBIOTICS 142
8.3.1.1 BY DRUGS 143
8.3.1.1.1 CIPROFLOXACIN 143
8.3.1.1.2 LEVOFLOXACIN 143
8.3.1.1.3 DOXYCYCLINE 143
8.3.1.1.4 AMPICILLIN 143
8.3.1.1.5 OTHERS 143
8.3.1.2 BY PRODUCT TYPES 144
8.3.1.2.1 GENERICS 144
8.3.1.2.2 BRANDED 144
8.3.1.2.2.1 CIPRO 144
8.3.1.2.2.2 LEVO 145
8.3.1.2.2.3 DOXY 145
8.3.1.2.2.4 AMPICI 145
8.3.1.2.2.5 OTHERS 145
8.3.2 ANTITOXINS 145
8.3.2.1 RAXIBACUMAB 145
8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
8.3.2.4 OTHERS 146
8.3.3 VACCINES 146
8.3.3.1 RAXIBACUMAB 146
8.3.3.2 SURGERY 146
8.4 INTESTINAL ANTHRAX 146
8.4.1 ANTIBIOTICS 148
8.4.1.1 BY DRUGS 148
8.4.1.1.1 CIPROFLOXACIN 148
8.4.1.1.2 LEVOFLOXACIN 148
8.4.1.1.3 DOXYCYCLINE 148
8.4.1.1.4 AMPICILLIN 149
8.4.1.1.5 OTHERS 149
8.4.1.2 BY PRODUCT TYPES 149
8.4.1.2.1 GENERICS 149
8.4.1.2.2 BRANDED 149
8.4.1.2.2.1 CIPRO 150
8.4.1.2.2.2 LEVO 150
8.4.1.2.2.3 DOXY 150
8.4.1.2.2.4 AMPICI 150
8.4.1.2.2.5 OTHERS 150
8.4.2 ANTITOXINS 151
8.4.2.1 RAXIBACUMAB 151
8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
8.4.2.4 OTHERS 151
8.4.3 VACCINES 152
8.4.3.1 RAXIBACUMAB 152
8.4.3.2 SURGERY 152
9 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153
9.1 OVERVIEW 154
9.2 PARENTERAL 157
9.3 ORAL 157
9.4 OTHERS 158
10 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER 159
10.1 OVERVIEW 160
10.2 GOVERNMENT ORGANIZATION 163
10.3 HOSPITALS 163
10.4 ACADEMIC AND RESEARCH 164
10.5 OTHERS 166
11 NORTH AMERICA VIRTUAL REALITY MARKET, BY GEOGRAPHY 167
11.1 NORTH AMERICA 168
11.1.1 U.S. 185
11.1.2 CANADA 195
11.1.3 MEXICO 205
12 NORTH AMERICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 215
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 215
13 SWOT ANALYSIS 216
14 COMPANY PROFILE 217
14.1 BAYER AG 217
14.1.1 COMPANY SNAPSHOT 217
14.1.2 REVENUE ANALYSIS 217
14.1.3 COMPANY SHARE ANALYSIS 218
14.1.4 PRODUCT PORTFOLIO 218
14.1.5 RECENT DEVELOPMENTS 218
14.2 PFIZER INC. 219
14.2.1 COMPANY SNAPSHOT 219
14.2.2 REVENUE ANALYSIS 219
14.2.3 COMPANY SHARE ANALYSIS 220
14.2.4 PRODUCT PORTFOLIO 220
14.2.5 RECENT DEVELOPMENTS 220
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 221
14.3.1 COMPANY SNAPSHOT 221
14.3.2 REVENUE ANALYSIS 221
14.3.3 COMPANY SHARE ANALYSIS 222
14.3.4 PRODUCT PORTFOLIO 222
14.3.5 RECENT DEVELOPMENT 222
14.4 SANOFI 223
14.4.1 COMPANY SNAPSHOT 223
14.4.2 REVENUE ANALYSIS 223
14.4.3 COMPANY SHARE ANALYSIS 224
14.4.4 PRODUCT PORTFOLIO 224
14.4.5 RECENT DEVELOPMENTS 224
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 225
14.5.1 COMPANY SNAPSHOT 225
14.5.2 REVENUE ANALYSIS 225
14.5.3 PRODUCT PORTFOLIO 226
14.5.4 RECENT DEVELOPMENT 226
14.6 ALEMBIC PHARMACEUTICALS LIMITED 227
14.6.1 COMPANY SNAPSHOT 227
14.6.2 PRODUCT PORTFOLIO 227
14.6.3 RECENT DEVELOPMENTS 227
14.7 ALTIMMUNE 228
14.7.1 COMPANY SNAPSHOT 228
14.7.2 REVENUE ANALYSIS 228
14.7.3 PRODUCT PORTFOLIO 229
14.7.4 RECENT DEVELOPMENTS 229
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 230
14.8.1 COMPANY SNAPSHOT 230
14.8.2 PRODUCT PORTFOLIO 230
14.8.3 RECENT DEVELOPMENTS 230
14.9 BLUEWILLOW BIOLOGICS. 231
14.9.1 COMPANY SNAPSHOT 231
14.9.2 PRODUCT PORTFOLIO 231
14.9.3 RECENT DEVELOPMENTS 231
14.10 DEINOVE 232
14.10.1 COMPANY SNAPSHOT 232
14.10.2 REVENUE ANALYSIS 232
14.10.3 PRODUCT PORTFOLIO 233
14.10.4 RECENT DEVELOPMENTS 233
14.11 EMERGENT 234
14.11.1 COMPANY SNAPSHOT 234
14.11.2 REVENUE ANALYSIS 234
14.11.3 PRODUCT PORTFOLIO 235
14.11.4 RECENT DEVELOPMENTS 235
14.12 ELUSYS THERAPEUTICS INC. 236
14.12.1 COMPANY SNAPSHOT 236
14.12.2 PRODUCT PORTFOLIO 236
14.12.3 RECENT DEVELOPMENTS 236
14.13 GC BIOPHARMA CORP. 237
14.13.1 COMPANY SNAPSHOT 237
14.13.2 REVENUE ANALYSIS 237
14.13.3 PRODUCT PORTFOLIO 238
14.13.4 RECENT DEVELOPMENTS 238
14.14 INDOCO REMEDIES LTD. 239
14.14.1 COMPANY SNAPSHOT 239
14.14.2 REVENUE ANALYSIS 239
14.14.3 PRODUCT PORTFOLIO 240
14.14.4 RECENT DEVELOPMENTS 240
14.15 INTEGRATED BIOTHERAPEUTICS, INC. 241
14.15.1 COMPANY SNAPSHOT 241
14.15.2 PRODUCT PORTFOLIO 241
14.15.3 RECENT DEVELOPMENTS 241
14.16 LUPIN. 242
14.16.1 COMPANY SNAPSHOT 242
14.16.2 REVENUE ANALYSIS 242
14.16.3 PRODUCT PORTFOLIO 243
14.16.4 RECENT DEVELOPMENTS 243
14.17 PARATEK PHARMACEUTICALS, INC. 244
14.17.1 COMPANY SNAPSHOT 244
14.17.2 REVENUE ANALYSIS 244
14.17.3 PRODUCT PORTFOLIO 245
14.17.4 RECENT DEVELOPMENTS 245
14.18 PORTON BIOPHARMA 246
14.18.1 COMPANY SNAPSHOT 246
14.18.2 PRODUCT PORTFOLIO 246
14.18.3 RECENT DEVELOPMENTS 246
14.19 SOLIGENIX 247
14.19.1 COMPANY SNAPSHOT 247
14.19.2 REVENUE ANALYSIS 247
14.19.3 PRODUCT PORTFOLIO 248
14.19.4 RECENT DEVELOPMENTS 248
14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 249
14.20.1 COMPANY SNAPSHOT 249
14.20.2 REVENUE ANALYSIS 249
14.20.3 PRODUCT PORTFOLIO 250
14.20.4 RECENT DEVELOPMENTS 250
14.21 ZYDUS GROUP 251
14.21.1 COMPANY SNAPSHOT 251
14.21.2 REVENUE ANALYSIS 251
14.21.3 PRODUCT PORTFOLIO 252
14.21.4 RECENT DEVELOPMENTS 252
15 QUESTIONNAIRE 253
RELATED REPORTS 255
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
